This white paper developed for Sandoz explores biosimilars. These drugs obtained by a biotechnological process similar to that of existing biologics, referred to as reference products, and for which the patent is in the public domain. How to encourage the uptake of biosimilars? What are the challenges and opportunities for the healthcare ecosystem?
Download our white paper for learn more.